Sequence-specific genomic DNA (DNA) (DNA)

Sequence-specific genomic DNA refers to the precise nucleotide sequences within the human genome that serve as the primary blueprint for cellular function and inheritance (National Human Genome Research Institute, 2023). As a therapeutic target, it is the focus of advanced genetic engineering technologies such as CRISPR-Cas9, zinc finger nucleases (ZFNs), and transcription activator-like effector nucleases (TALENs), which are designed to recognize and modify specific loci to treat genetic diseases (Doudna & Charpentier, 2014, Science). Beyond gene editing, certain small molecules and synthetic polyamides can bind to the minor or major grooves of DNA in a sequence-selective manner to modulate gene expression (Neidle, 2001, Nature Reviews Drug Discovery). Targeting genomic DNA allows for the correction of underlying genetic defects, such as those found in sickle cell disease or cystic fibrosis, rather than merely managing symptoms (Steinberg, 2020, American Journal of Hematology). The primary challenge in targeting specific DNA sequences is ensuring high fidelity to avoid off-target mutations, which could lead to oncogenesis or other unintended cellular consequences (Zhang et al., 2015, Cell). This target class represents a paradigm shift in medicine from protein-centric pharmacology to direct genome modulation. Clinical applications include the use of ex vivo gene editing to modify hematopoietic stem cells for the treatment of hemoglobinopathies (Frangoul et al., 2021, NEJM).

Other names

Genomic DNATarget DNA sequenceChromosomal DNASequence-selective DNA

Sequence-specific binding followed by enzymatic cleavage, transcriptional interference, or chemical modification of the DNA structure to modulate gene expression or repair genetic defects.